Overview

• Milestone Scientific Q3 revenue decreased slightly due to lower domestic dental sales

• Operating loss improved by 23% due to cost-reduction initiatives

• Net loss narrowed to $1.2 mln from $1.5 mln in Q3 2024

Outlook

• Company expects improved margins and revenue stability from operational transformation

• Milestone Scientific advancing reimbursement strategy for broader adoption of CompuFlo®

• Company sees growing interest in CompuFlo® from hospitals and international distributors

Result Drivers

• COST MANAGEMENT - Co reduced operating expenses by over $0.5 mln through disciplined cost management and restructuring

• DENTAL SEGMENT EXPANSION - Co expanded direct sales programs in North America and secured new international registrations for STA® System

• MEDICAL SEGMENT GROWTH - Growing utilization of CompuFlo® disposables and progress in reimbursement strategies boosted recurring revenue

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Milestone Scientific Inc is $2.00, about 82% above its November 12 closing price of $0.36

Press Release: ID:nGNX3cLwZp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)